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Numerous published studies have documented the rapid rise in antimicrobial drug
resistance among common respiratory pathogens, particularly Streptococcus pneumoniae.
Yet, surprisingly few studies have evaluated the impact of these in vitro ﬁndings on
clinical outcomes. Outcomes research is the measurement of the impact of illness and the
effect of treatment on clinically relevant end-points. Studies of patients with community-
acquired pneumonia have established certain expected rates of outcomes, including
mortality, clinical complications, and time to resolution of symptoms. Recent studies
have identiﬁed speciﬁc processes of care and treatment choices that have an impact upon
these outcomes. However, there are no well-controlled studies that provide deﬁnitive
estimates of the magnitude of the impact of antimicrobial therapy on these outcomes for
patients with community-acquired pneumonia or other respiratory tract infections, such
as acute exacerbations of chronic bronchitis. Most studies of the impact of drug resistance
on outcomes for patients with respiratory tract infections have focused on the impact of
b-lactam drug resistance on outcomes for patients with community-acquired pneumo-
coccal pneumonia. In general, these studies have demonstrated that outcomes are not
affected by current levels of drug resistance, but most studies are hampered by small
sample size, inability to control adequately for severity of illness and concordance of
therapy, and inclusion of few subjects with high-level drug resistance. Additional studies
are urgently needed to assess better whether the current empiric treatment guidelines are
adequate or will need to be adjusted as patterns of resistance continue to evolve.
Keywords Antimicrobial, mortality, morbidity, outcome, pneumonia, resistance, patient
outcomes, cohort studies
INTRODUCTION
Over the last decade, there has been a rapid
increase in the number of published reports doc-
umenting the increasing prevalence of antimicro-
bial drug resistance among almost all common
bacterial pathogens. Indeed, entire conferences
and journals are now devoted to this topic. In
contrast, there is an extremely limited number of
published studies addressing the impact of bacter-
ial drug resistance on clinically relevant outcomes.
The purpose of this paper is to summarize the
results of outcomes research in the area of anti-
biotic resistance and lower respiratory tract infec-
tions (LRTIs) and to provide a framework for
interpreting future studies.
This paper is organized in three parts. First, the
broad principles of outcomes research are sum-
marized as they relate to the ﬁeld of LRTIs. Second,
is a summary of the results from outcomes research
onLRTIsand the impactofantimicrobial therapyon
these outcomes. Third, recent studies are reviewed
that have deﬁned the clinical impact of emerging
antibiotic resistance on outcomes for LRTIs. The
primary focus will be on patients with commu-
nity-acquiredpneumonia(CAP).However,patients
with acute exacerbations of chronic bronchitis
(AECB), which represents the other major type of
antibiotic-responsive LRTI, will also be considered.
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OUTCOMES RESEARCH
Outcomes research encompasses a broad array of
studies that measure the impact of illness and the
effect of treatment. As summarized in Table 1,
outcome measurements range from biologic end-
points to clinical end-points to economic end-
points. Clinical end-points, in particular, encom-
pass a wide range, including mortality, symptom
resolution, functional assessments and quality of
life measures [1]. Outcomes research emphasizes
the importance of clinically meaningful measures
rather than simply relying on physiologic or bio-
chemical outcomes. However, even though there
is an emphasis on clinical outcomes, there is still a
recognition that these clinically relevant changes
are driven by changes in more proximal, physio-
logical end-points. Thus, our approach to out-
comes research should be driven by some sense
of a causal pathway, requiring changes in prox-
imal biologic end-points to proceed to measurable
changes in distal end-points, such as symptoms,
quality of life, and functional status [2]. An overall
goal of outcomes research is to provide the data
necessary to translate the impact of changes in
therapy into predictable, quantiﬁable changes in
clinical end-points.
Studies of outcomes can adopt one of several
perspectives inquantifying the impactof illness and
its treatment, including individual patient, health-
care system and societal perspectives [1]. The per-
spective of the outcomes research dictates not only
the magnitude of the measured effects but also the
types of measures included in the analysis. For
example, patient perspectives typically emphasize
clinical end-points and quality of life, health-care
systemperspectives emphasize ﬁnancial outcomes,
and global perspectives emphasize combined end-
points, such as disability-adjusted life years.
In assessing the impact of antimicrobial drug
resistance on the treatment of patients with LRTIs,
outcomes research must focus on two key ques-
tions. First, what is the impact of appropriate
antimicrobial therapy on outcomes for patients
with LRTIs in the setting of susceptible organisms
and second, what is the impact of antimicrobial
drug resistance on these same outcomes? The ﬁrst
question provides a basic measure of the maxi-
mum negative impact of emerging resistance if a
drug loses all efﬁcacy. The second question add-
resses the measurable negative impact of emerging
resistance at current levels of drug resistance.
OUTCOMES FROM LOWER
RESPIRATORY TRACT INFECTIONS
Community-acquired pneumonia
Fundamentally, the most proximal outcome to
measure in patients with CAP is the success or
failure of bacterial eradication. Unfortunately,
measurement of bacterial eradication is relatively
uncommon in the everyday care of most patients
with CAP, and thus it is generally not possible to
determine the frequency of successful bacterial
eradication. Substantial information on processes
of care and outcomes for patients with CAP was
recently provided by the Agency for Health-Care
Policy and Research through their Patient Out-
comes Research Team’s study of pneumonia
(Pneumonia PORT). This prospective cohort study
was conducted from 1991 to 1994 and included
2287 hospitalized and ambulatory patients with
CAP from three different geographic sites in North
America (Pittsburgh, PA; Boston, MA; andHalifax,
NS). Data on processes and outcomes of care were
collected throughout the period of hospitalization
and at 7, 30 and 90days after the time of diagnosis.
In the Pneumonia PORT study, a total of 95.7% of
Table 1 Outcome measurements for patients with lower respiratory tract infections (adapted from [1] with permission)
Outcome Types Examples
Biologic Bacterial eradication Follow-up blood or sputum cultures
Clinical Mortality Community-acquired pneumonia 30-day mortality
Clinical events In-hospital complications
Time to stability
Symptoms Time to cough resolution
Quality of life Medical outcomes study Short Form-36
Economic Direct medical Length of hospital stay
Indirect medical Time to return to work
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hospitalized patients with CAP had microbiologic
studies performed, resulting in a bacterial patho-
gen being identiﬁed in 29.6% of cases. In contrast, a
total of 29.7% of outpatients with CAP had micro-
biologic studies sent, resulting in a bacterial patho-
gen being identiﬁed in only 5.7% of cases [3].
Regardless of these ﬁndings, animal studies have
strongly suggested that bacterial eradication is
critical for the successful treatment of patients with
CAP [4].
Mortality
Mortality is the most common clinical end-point
assessed in studies of CAP. In a review of outcome
studies in 1997, 127 study cohorts included mor-
tality as a primary outcome measurement. Only 41
of these 127 study cohorts (32%) included addi-
tional outcome measures, such as rates of morbid
complications. Mortality estimates from these stu-
dies have varied widely depending on the site of
care (5.1% for outpatients plus inpatients vs. 13.6%
for inpatients alone), the pathogen identiﬁed (1%
for Mycoplasma pneumoniae vs. 12.3% for Strepto-
coccus pneumoniae), and coexisting clinical features
(e.g. 19.6% for patients with bacteremia) [5]. This
variation has limited the ability to compare out-
comes of care across different sites or over time. As
a result there has been considerable interest in the
development of CAP-speciﬁc severity of illness
measures that would allow adjustment of baseline
differences related to mortality outcomes. One
such tool, the Pneumonia Severity Index (PSI),
was developed from a cohort of 14 199 adult inpa-
tients with CAP and validated in a cohort of 2287
inpatients and outpatients in the Pneumonia
PORT study. This index, comprising 20 variables,
predicts 30-day mortality and permits severity
adjustment for mortality outcome comparisons
across disparate sites and times [6]. In its current
form, the PSI emphasizes acuity of illness and
background of co-morbidity but not microbiologic
etiology. As we shall discuss, the availability of
accurate severity adjustment tools is critical to
measuring the independent impact of antibiotic
resistance on clinical outcomes.
Surprisingly, there are extremely limited data to
assess the impact of medical therapy on mortality
for patients with CAP. Since the introduction of
penicillin therapy in the mid-1940s, there have not
been any placebo-controlled trials assessing the
impact of antibiotic therapy because antibiotic
therapy is uniformly considered the standard of
care. In 1964, Austrian and Gold compared out-
comes for patients with CAP in the pre- and post-
antibiotic eras and observed that mortality from
bacteremic pneumococcal CAP had declined over-
all, but not during the ﬁrst 5 days of therapy
(Figure 1) [7]. This ﬁnding is likely to be explained
by the observation that antimicrobial therapy alone
is insufﬁcient to turnoff thedown-streammediators
associated with an established sepsis cascade.
More recently, observational studies have iden-
tiﬁed speciﬁc process of care measures that appear
to be associated with reduced mortality in patients
with CAP even after adjustment for baseline dif-
ferences in severity of illness. In particular, admin-
istration of antibiotics within 8 h of presentation to
an emergency department was associated with a
15% decreased odds of death among patients hos-
pitalized with CAP [8]. In addition, compared to
administration of a third-generation cephalosporin
alone, administration of either a second- or third-
generation cephalosporin combined with a macro-
lide,oraﬂuoroquinolonealone,wasassociatedwith
a 30–40% reduction in short-term mortality [9].
Hypothesized mechanisms responsible for the
improved outcomes include improved coverage
for atypical pathogens or, in the case of drug combi-
nations, improved killing of selected pathogens,
particularly S. pneumoniae, with the simultaneous
use of multiple active agents. However, the precise
basis for these ﬁndings remains unknown.
Figure 1 Effect of therapy on percentage survival in
pneumococcal bacteremia. Numbers in parentheses indi-
cate size of each group of patients (reproduced from [7]
with permission).
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These results provide an estimate of the increase
inmortality that might be expected in the setting of
inadequate antimicrobial therapy because of drug
resistance. However, the nonexperimental nature
of these studies limits the validity of these ﬁnd-
ings. Residual confounding might be expected to
exaggerate the observedmortality differences [10].
For example, physicians may include macrolide
therapy when they suspect an atypical pathogen
such as Chlamydia or Mycoplasma spp., which are
associatedwith a reducedmortality rate compared
to S. pneumoniae. On the other hand, because all
patients in these studies received some antibiotic
therapy, the magnitude of the survival beneﬁt
attributed to appropriate antimicrobial therapy
may underestimate the impact of patterns of drug
resistance that render speciﬁc therapy completely
ineffective.
Global impact
When aggregated at a global level, the impact of
mortality from CAP is substantial. A recent project
supported by the World Health Organization and
the Harvard School of Public Health provided
estimates of the burden of death attributable to
LRTIs in both the developed and developing
world. Based on 1990 data, LRTIs were the leading
cause of death in developing regions (3.9 million
deaths annually) and the fourth leading cause of
death in developed regions (385 000 deaths
annually) [11]. Thus, even small relative increases
in the mortality rate for CAP resulting from anti-
biotic resistance would translate into substantial
increases in the numbers of deaths as a result of
CAP at a global level.
In-hospital outcomes
In addition to mortality, clinical outcomes mea-
sured during hospitalization include clinical com-
plications, such as respiratory failure, shock and
empyema, as well as simply prolonged time to
clinical stability. Average rates of clinical compli-
cations for hospitalized patients range from 5% for
empyema to 8% for respiratory failure or shock,
but individual rates vary substantially depending
on the underlying severity of illness [5]. Time to
clinical stability is an aggregated measure of the
time to normalization of vital signs (heart rate,
systolic blood pressure and respiratory rate), oxy-
genation status, ability to take food by mouth, and
mental status. This outcome measure was recently
validated as a measure of clinical recovery in
hospitalized patients with CAP. In the Pneumonia
PORT study, the median time to stability ranged
from 3 to 7 days depending on the particular vital
sign thresholds chosen [12]. The impact of anti-
microbial therapy on rates of clinical complica-
tions or time to clinical stability has yet to be
determined.
Economic impact
In-hospital outcomes have a critical impact on the
costs of care for patients with CAP. In the USA
alone, the total cost of CAP care was estimated at
over US$ 9 billion for 1994, of which 92% was a
result of the costs of inpatient care [13]. The rate of
admission, inpatient resource utilization and
length of hospital stay are critical components of
the overall costs of care for CAP. These costs have
been shown to vary signiﬁcantly across hospitals,
primarily because of variations in length of stay
[14]. Whether antimicrobial therapy speciﬁcally
impacts on the length of hospitalization, and thus
overall costs of care, is largely unknown.However,
in one observational study, patients with CAP
treated with macrolides had signiﬁcantly shorter
lengths of hospital stay compared to patients trea-
ted with alternative drug regimens (2.8 days vs.
5.3 days) [15]. Because this study did not have a
controlled experimental design, the decrease in
length of stay may be explained by residual con-
founding by differences between the groups in the
severity of illness.
Functional outcomes
Recently, there has been a growing awareness of
the importance of symptomatic and functional
outcomes in the assessment of quality of care.
Overall, these measures provide support for the
conclusion that CAP leads to substantial morbidity
and functional loss. For example, even among low-
risk patients with CAP, the median time to cough
resolution is 14 days [16] and 20% of patients still
report substantial fatigue at 3months from the
time of diagnosis [17]. Measures of physical func-
tion remain depressed weeks to months after the
diagnosis of CAP. For example, mean scores for
the physical functioning domain of the Medical
Outcomes Study Short Form 36 questionnaire re-
main signiﬁcantly below pre-illness levels 30 days
from the time of diagnosis [17]. Consistent with
this observation, only 57% of patients hospitalized
with CAP report returning to usual activities
by 30 days [3]. Although CAP disproportionately
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affects the elderly, it remains a signiﬁcant cause of
lost days of work. In the Pneumonia PORT study,
the median number of days of lost work (among
those employed at the time of diagnosis) was
7 days [3]. However, despite the importance of
these measures in assessing the total impact of
CAP, little or no information is available to assess
the impact of antimicrobial therapy on any of these
measures.
Acute exacerbations of chronic bronchitis
In contrast to the large number of outcome studies
enrolling patients with CAP, there is a much
more limited body of evidence underlying our
knowledge about the natural history of AECB
and the impact of antibiotic therapy on those out-
comes. The overall mortality associated with
exacerbations requiring hospitalization is 3–4%,
although this can be as high as 11–24% among
those requiring admission to an intensive-care
unit. Functional decline after an acute exacerbation
can be signiﬁcant and re-admission is common
[18].
Studies that have assessed the impact of anti-
biotic therapy on outcomes for patients with AECB
have utilized a variety of measures, including
duration of illness, symptom scores and peak
expiratory ﬂow rate [18]. Systematic reviews have
concluded that antibiotics do improve peak
expiratory ﬂow rates [19]. In general, the beneﬁts
of antibiotics are more apparent for patients with
more severe exacerbations. For example, patients
with more severe attacks have greater symptom
reduction with antibiotics, but patients with mild
attacks have similar outcomes with or without
antibiotic therapy [18].
In summary:
 CAP results in substantial mortality and mor-
bidityatpatient,healthsystem,andsocietallevels.
 Appropriate antimicrobial therapy appears to
reduce CAP-related mortality by as much as
40%. However, these estimates are based on
nonexperimental data and may be confounded.
Extrapolation of such data to the question of
antimicrobial drug resistance is uncertain.More-
over, themajority of randomized clinical trials in
this area focus on antibiotic–antibiotic compar-
isons, and are generally underpowered to detect
differences in efﬁcacy.
 Additional outcomes measures, such as time to
stability, rates of clinical complications, and
functional recovery may be more sensitive mar-
kers of the adequacy of antimicrobial drug ther-
apy but there are virtually no data relating
therapy to any of these outcomes.
 The impact of antimicrobial therapy on other
LRTIs is marginal. The strongest evidence of a
beneﬁt is in patients with severe AECB.
 The majority of outcomes research on patients
with LRTIs has been based in the USA and other
developed countries. Given the global burden of
these illnesses, and the variability in health-care
delivery systems world-wide, it is crucial that
outcomes studies increasingly include patients
from developing countries to assess better the
global clinical and economic impact of emerging
resistance.
IMPACT OF DRUG RESISTANCE
General principles
Over the last 10 years, multiple studies have docu-
mented the rapid rise in drug resistance among
common community-acquired respiratory patho-
gens, particularly S. pneumoniae, Haemophilus inﬂu-
enzae and Moraxella catarrhalis (reviewed by
Felmingham et al. [20]). Yet, there have been an
extremely limited number of controlled studies
documenting clinical failures as a result of this
rapidly emerging drug resistance. Why have
increasing rates of drug resistance among bacteria
isolated from clinical infections not translated into
easily recognizable rates of treatment failure with
speciﬁc antibiotic drugs? The major methodologic
challenges underlying research in this area are
summarized in Table 2. First, as discussed earlier,
although antimicrobial therapy has become the
standard of care for patients with bacterial infec-
tions such as CAP and AECB, in reality, data
demonstrating the impact of drug therapy on
outcomes for these illnesses are limited. Among
high-risk patients, a substantial number of patients
die despite adequate antibiotic therapy. Among
low-risk patients, few patients die even in the
absence of antibiotic therapy. Thus, mortality
from CAP may be a relatively insensitive measure
of the impact of drug resistance. On the other
hand, other outcome measures may be more sen-
sitive to rates of drug resistance, but we have
extremely limited data in this area and much of
these are derived from comparisons of patients on
different antibiotics at a time when rates of resis-
tance were low.
European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 1–11
Metlay and Singer Impact of resistance on outcomes 5
Second, the standardized interpretations of
levels of bacterial inhibition by drugs in vitro do
not necessarily reﬂect true drug levels in vivo [21].
Thus, substantial numbers of clinical infections are
mislabeled as resistant to common antimicrobial
drugs and therefore should not be expected to fail
with therapy with these drugs [22].
Third, drug resistance will only translate into
clinical failures if clinicians continue to use agents
that are affected by the resistance mechanisms
displayed by the bacteria, a form of therapy
labeled ‘discordant’ therapy. For example, discor-
dant therapy occurs when a patient infected with
macrolide-resistant S. pneumoniae receives macro-
lide monotherapy, but not if the same patient is
treated with a ﬂuoroquinolone. In the latter set-
ting, macrolide resistance would not be expected
to have an impact on outcomes. Recent trends in
antimicrobial drug prescribing in the USA suggest
that physicians move on to newer therapies very
soon after the emergence of resistance to older
drugs, thus limiting the frequency of observable
discordant therapy in most outcomes studies
[23].
Impact on mortality
A number of case reports have suggested that
antimicrobial resistance among clinical isolates
of S. pneumoniae is associated with treatment fail-
ures among patients with LRTIs. However, since
1987, there have been only seven controlled
studies comparing mortality for adult patients
with predominantly respiratory infections caused
by penicillin-resistant and penicillin-susceptible
S. pneumoniae (Table 3) [24–30]. Four of these
studies reported no signiﬁcant impact of anti-
microbial resistance on mortality following pneu-
mococcal infection [25–27, 29]. These results
were particularly noted after adjustment for dif-
ferences in baseline severity of illness and discor-
dance of therapy, as deﬁned above. For example,
in one study, the unadjusted relative risk of death
was 2.1 comparing patients infected with penicil-
lin-resistant vs. penicillin-susceptible S. pneumo-
niae. After adjustment for differences in baseline
severity of illness, the relative risk was reduced
to 1.7 and no longer statistically signiﬁcant. More-
over, after adjustment for discordance of therapy,
the relative risk was further reduced to 0.8, sug-
gesting that there was no impact of discordant
therapy on mortality outcomes in this illness
[29]. Similarly, another study measured a relative
risk of death of 2.8 (95% CI 0.8–10.1) compar-
ing patients with penicillin nonsusceptible and
penicillin-susceptible pneumococcal pneumonia.
However, the relative risk was only 1.2 (95% CI
0.3–5.3) when comparing patients with penicillin-
resistant and penicillin-susceptible pneumococcal
pneumonia after adjusting for discordance of ther-
apy [27]. It should be noted, however, that the
majority of resistant infections in these studies
included bacteria with ‘intermediate’ levels of
penicillin resistance with minimum inhibitory con-
centrations (MICs) in the 0.1–1.0mg/L range, as
opposed to ‘high-level’ resistance (MIC2mg/L),
which would be expected to have a greater impact
on outcomes and which are increasing in
frequency.
Among the three studies that identiﬁed a sig-
niﬁcant impact on mortality, one study did not
adjust for baseline differences in severity of illness
[24]. A second study focused on patients with
human immunodeﬁciency virus infection and
Table 2 Methodologic challenges in assessing the impact of antibiotic resistance on medical outcomes for patients with
lower respiratory tract infections
Methodologic challenge Impact on outcomes studies Solution
Antibiotic efficacy only partially
determines outcomes
Decreases power of studies to
detect the impact of drug resistance
Increase sample size of outcomes
studies
Interpretation of in vitro levels
of susceptibility not correlated
with in vivo predictions of pharmacokinetic/
pharmacodynamic models
Misclassification of patients
as exposed to resistant infections
Apply pharmacokinetic/
pharmacodynamic predicted
breakpoints to interpretation
of susceptibility results
Drug resistance only effects outcomes
in setting of discordant therapy
Misclassification of patients
as exposed to resistant infections
Consider both treatment and
pathogen susceptibility in
interpreting outcomes research
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pneumococcal bacteremia and measured an
increased mortality for those patients infected
with resistant bacteria. Of note, the majority of
isolates in this study demonstrated high-level
resistance (MIC> 1.0mg/L) [28]. Moreover, it is
plausible that patients with immunodeﬁciencies
represent a particular group at risk of adverse
outcomes in settings where antimicrobial therapy
has reduced efﬁcacy. A third study of patients
with invasive pneumococcal pneumonia did not
measure a signiﬁcant impact of penicillin and
cefotaxime resistance on overall mortality after
adjusting for underlying severity of illness. How-
ever, after excluding deaths occurring during the
ﬁrst 4 days of hospitalization, a signiﬁcant risk
of death was noted for pneumococcal infections
with penicillin MIC 4.0mg/L or cefotaxime
MIC 2.0mg/L [30]. The rationale for this
approach was based on the historical observa-
tion—noted earlier—that antibiotic therapy has
had minimal impact on the early mortality rate
from bacteremic pneumococcal pneumonia [7].
However, this study did not include data on anti-
microbial therapy and therefore the impact of
discordant therapy on mortality could not be
assessed.
Impact on in-hospital outcomes
Few studies have assessed the impact of drug re-
sistance on outcomes other than mortality. In one
study, length of stay and rates of complications
were not signiﬁcantly worse for patients with anti-
microbial-resistant pneumococcal infections [27].
However, another study identiﬁed a signiﬁcant
4.8-fold increase in the risk of suppurative com-
plications (i.e. empyemas) among patients with
penicillin-resistant compared to penicillin-suscep-
tible pneumococcal pneumonia, even after adjust-
ing for differences in baseline severity of illness
[29]. After adjusting for the discordance of anti-
microbial therapy, this increased risk was no
longer apparent, but the small number of discor-
dant cases resulted in extremely wide conﬁdence
intervals for the estimated risk (J.P.M., unpub-
lished observations). No studies have assessed
the impact of drug resistance on post-discharge
outcomes, e.g. symptom resolution and return to
usual activities.
Impact on outpatient care
Controlled studies measuring the impact of drug
resistance on outcomes of care for outpatients with
Table 3 Impact of penicillin susceptibilitya on mortality for adults with community-acquired pneumococcal pneumonia
Study Subjects Sample size
Relative risk of death for
nonsusceptible vs. susceptible
infections
Pallares et al. 1987 [24] Bacteremic pneumococcal
pneumonia
24 penicillin nonsusceptible 2.2
48 penicillin susceptible (P¼ 0.03)
Pallares et al. 1995 [25] Pneumococcal pneumonia 145 penicillin nonsusceptible 1.0b
359 penicillin susceptible (95% CI 0.5–1.9)
Winston et al. 1999 [26] Pneumococcal infection 65 penicillin nonsusceptible 1.25
411 penicillin susceptible (P¼ 0.82)
Ewig et al. 1999 [27] Pneumococcal pneumonia 49 penicillin nonsusceptible 2.8
52 penicillin susceptible (95% CI 0.8–10.1)
Turett et al. 1999 [28] Pneumococcal bacteremia 20 penicillin resistantc 6.0b
429 penicillin susceptible (P< 0.02)
Metlay et al. 2000 [29] Bacteremic pneumococcal
pneumonia
44 penicillin nonsusceptible 1.7b
148 penicillin susceptible (95% CI 0.8–3.4)
Feikin et al. 2000 [30] Invasive pneumococcal
pneumonia
183 penicillin resistantd 7.1e
3452 penicillin susceptible (95% CI 1.7–30.0)
aPenicillin nonsusceptible defined as intermediate susceptible plus resistant (MIC> 0.1mg/L); badjusted for severity of
illness; cresistant defined as MIC> 1.0 mg/mL; dresistant defined as MIC 4.0mg/L; eadjusted for severity of illness, and
deaths during first 4 days of hospitalization excluded.
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CAP are not available. In part, this reﬂects the
general principle that adverse outcomes because
of therapeutic failure are more likely to occur
among severely ill patients than among lower-risk
patients for whom the impact of adequate anti-
microbial therapy is marginal. On the other hand,
because most outpatients with CAP are treated
with a course of a single antimicrobial agent and
most inpatients are treated with multiple antimi-
crobial drugs, outpatients may be more likely to
receive discordant therapy. As a result, although
the consequences of discordant therapy may be
less severe, the increased frequency of discordant
therapy may translate into signiﬁcant numbers of
therapeutic failures. In support of this hypothesis,
recently published case reports have described
patients with CAP who failed outpatient therapy,
subsequently required hospitalization, and had
macrolide-resistant S. pneumoniae isolated from
blood cultures at the time of hospitalization [31].
The relatively small number of such case reports
suggests that the current rate of such treatment
failures is low, but large-scale controlled studies of
outpatient care are needed to measure more accu-
rately the rates of treatment failure because of
antimicrobial resistance.
Impact of resistance mechanisms on outcomes
Virtually all controlled studies of the impact of
resistance on outcomes for patients with CAP have
focused on the impact of penicillin resistance.
Controlled studies of the impact of macrolide or
ﬂuoroquinolone resistance on CAP outcomes are
clearly needed. Indeed, given differences in the
mechanisms of drug resistance and pharmacoki-
netic/pharmacodynamic properties of the differ-
ent antimicrobial agents, it is highly likely that
similar levels of in vitro antimicrobial drug resis-
tance will translate into different rates of clinical
failure for different classes of antimicrobial agents.
Ultimately, as discussed earlier, the focus of out-
comes studies for patients with CAP should assess
the impact of different forms of discordant therapy
rather than focus on the patterns of bacterial resis-
tance alone.
Costs of care
There are limited data on the direct economic
impact of antimicrobial resistance among patients
with LRTIs. As noted in a recent report from the
Institute of Medicine, the impact of resistance on
costs of care can include the direct medical costs of
extended hospital time and extra physician visits,
the costs of newer antibiotics to replace the older
antibiotics that are abandoned because of emer-
ging resistance, and indirect costs because of loss
of productivity [32]. While mathematical models
have provided overall cost estimates of the impact
of antimicrobial drug resistance (up to US$ 3 bil-
lion annually in the USA alone), most direct-cost
estimates have focused on nosocomial infections,
particularly those as a result of methicillin-resis-
tantStaphylococcus aureus [32].Nodatahavedirectly
assessed the economic impact of resistance on the
care of patients with respiratory tract infections.
Impact of antimicrobial resistance on outcomes
for acute exacerbations of chronic bronchitis
We are unaware of any studies that have directly
assessed the impact of antimicrobial drug resis-
tance on outcomes for patients with AECB. It is
notable that the majority of studies investigating
the impact of antibiotic therapy on outcomes from
AECB were conducted at a time when levels of
antimicrobial drug resistance were generally too
low to impact on outcomes. In addition, the overall
small impact of antibiotics on these outcomes
suggests that increasing antibiotic resistance is
unlikely to have a substantial impact on outcomes
from these illnesses [33]. On the other hand, the
impact of adequate antimicrobial therapy may be
far greater among patients with the most severe
forms of chronic obstructive lung disease. There-
fore, emerging antimicrobial drug resistance
may lead to a much higher rate of clinically sig-
niﬁcant therapeutic failures among this subset of
patients.
As with CAP, there is increasing interest in the
use of alternatives to mortality as potentially more
sensitive outcome measures for assessing the ade-
quacy of antimicrobial therapy in AECB. For
example, ‘time to next exacerbation’ may be an
outcome that has particular clinical meaningful-
ness and signiﬁcant economic implications [34]. If
this measure is sensitive to differences in the
adequacy of antimicrobial therapy, it should be
used as an end-point in future studies. Regardless
of this, future studies on the impact of adequate
antimicrobial therapy on outcomes for patients
with AECB are clearly needed because nearly all
of the currently available data were collected prior
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to the recent emergence of antimicrobial resistance
among the relevant respiratory pathogens.
FUTURE DIRECTIONS
Antimicrobial drug resistance among respiratory
tract pathogens is a dynamic problem. Rates of
resistance, particularly multidrug resistance, are
rapidly rising. In addition, clinical practice guide-
lines for the treatment of LRTIs, particularly CAP,
are continually being revised, resulting in chan-
ging treatment strategies in the face of resistance
(reviewed by Finch and Low [35]). Thus, studies
on outcomes from as recent as 5–10 years ago may
have limited relevance for current clinical practice.
Moreover, in contrast to the abundance of micro-
biologic studies documenting the patterns of anti-
microbial drug susceptibility, there have been an
extremely limited number of studies examining
the clinical relevance of this phenomenon. Finally,
there is an increasing awareness that mortality is
only one of several clinically and economically
important outcomes to measure. However, very
few studies have considered the impact of resis-
tance on nonmortality outcomes.
Overall, there is a clear need for more studies
in this area. Ongoing clinical trials of new anti-
microbial drugs and large electronic patient data-
bases with detailed pharmaceutical and laboratory
data should be evaluated as important settings
for future studies of the impact of resistance on
outcomes. Studies should focus not only on high-
risk subjects who are most likely to experi-
ence adverse outcomes but also on lower-risk
settings where single-drug therapy raises the
probability (and consequences) of discordant
therapy.
CONCLUSIONS
In conclusion:
 Despite the high rates of drug resistance that
have been reported by surveillance systems of
respiratory tract isolates, few controlled studies
have demonstrated adverse effects of this resis-
tance on clinical outcomes.
 The majority of clinical outcome studies ex-
amining the impact of drug resistance in
respiratory tract infections have focused on
hospitalized patients with CAP as a result of
S. pneumoniae and the impact of resistance to
penicillin.
 Outcome studies cannot be interpreted if they
do not adjust for differences in baseline severity
of illness and the discordance of antimicrobial
therapy.
 Explanations for the limited observed clinical
impact of drug resistance include the discre-
pancy between in vitro levels of resistance and
in vivo levels of resistance predicted by phar-
macokinetic/pharmacodynamic models, the
lack of discordant therapy in many studies,
and—especially—the fact that clinical outcomes
from LRTIs are not solely dependent on the
adequacy of antimicrobial therapy, thus limiting
the power of most current studies to detect an
impact. These issues should all be considered in
the design and interpretation of future studies of
the impact of drug resistance on clinical out-
comes.
 Despite these limitations, recent case reports and
some controlled studies suggest that antimicro-
bial drug resistance is leading to increased rates
of adverse outcomes among patientswith LRTIs,
particularly CAP. These studies are notable for
their focus on patients with HIV, patients
infected with highly penicillin-resistant S. pneu-
moniae, and patients with macrolide-resistant
S. pneumoniae.
 Given the critical importance of outcomes stu-
dies for deﬁning empiric treatment guidelines
and the rapid evolution of antimicrobial drug
susceptibility patterns, additional studies are
needed now, particularly in developing coun-
tries where levels of drug resistance are espe-
cially high and therapeutic options are limited.
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